Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot
This article was originally published in The Pink Sheet
The firm lowers its 2016 guidance as its European branded OTC drug and nutritional product business and its Rx topicals business appear to be major obstacles to escaping its earnings slump.
You may also be interested in...
A repeat of FDA’s record-breaking NME approval performance from recent years looks unlikely, even though the 14 novel approvals in the first half of 2016 equals the first half total for 2015, because almost one-third fewer novel candidates have user fee goals in the second half.
The cash deal for Perrigo's vitamins, minerals and supplements business will make International Vitamin Corporation the largest US private label nutritional product manufacturer and better position Perrigo to either continue on its own or as an even more attractive takeover target.
The latest drug development news and highlights from our FDA Performance Tracker.